To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Dipeptidyl peptidase-4 inhibitors
Additional recommended knowledge
Inhibitors of Dipeptidyl peptidase 4 , also DPP-4 inhibitors, are a new class of oral hypoglycemics which block DPP-4.
Their mechanism of action is thought to result from increased Incretin levels (GLP-1 and GIP), which, inhibit glucagon release (which increases the blood glucose) but more importantly increase insulin secretion and decrease gastric emptying.
Drugs belonging to this class are vildagliptin, sitagliptin and saxagliptin.
Although extensive long-term, pre-clinical studies of the major DPP-4 inhibitors has failed to show any evidence of potential to cause tumors in laboratory animals, there was one in-vitro (i.e., test tube) study that has raised some questions. 
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dipeptidyl_peptidase-4_inhibitors". A list of authors is available in Wikipedia.|